Eutilex.Co.Ltd Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Byoung S. Kwon

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.9yrs
CEO ownership	15.0%
Management average tenure	no data
Board average tenure	no data

Recent management updates

No updates

Recent updates

Is Eutilex.Co.Ltd (KOSDAQ:263050) A Risky Investment?

Apr 15

Could The Eutilex.Co.,Ltd. (KOSDAQ:263050) Ownership Structure Tell Us Something Useful?

Feb 05

CEO

Byoung S. Kwon

1.9yrs

Tenure

Dr. Byoung S. Kwon, Ph.D. is the Founder and serves as Chief Executive Officer of Eutilex Co., Ltd. Dr. Kwon serves as Endowed Investigator at the Division of Cell and Immunobiology of R&D Center for Cance...

Eutilex.Co.Ltd Management

Management criteria checks 0/4

Key information

Recent management updates

Recent updates

New major risk - Financial position

Is Eutilex.Co.Ltd (KOSDAQ:263050) A Risky Investment?

New minor risk - Market cap size

New major risk - Shareholder dilution

Eutilex.Co.,Ltd. has completed a Follow-on Equity Offering in the amount of KRW 51.59 billion.

Eutilex.Co.,Ltd. has completed a Follow-on Equity Offering in the amount of KRW 51.59 billion.

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Eutilex.Co.,Ltd. announced that it has received KRW 22.5003376 billion in funding

Eutilex.Co.,Ltd. announced that it expects to receive KRW 22.5003376 billion in funding from Asset One Asset Management, Focus Asset Management Co., Ltd., SUSUNG ASSET MANAGEMENT Co., Ltd., GVA Asset Management Co., Ltd., W Asset Management Co., Ltd., Brain Asset Management Co., Ltd.

Could The Eutilex.Co.,Ltd. (KOSDAQ:263050) Ownership Structure Tell Us Something Useful?

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

New 90-day high: ₩40,300

New 90-day high: ₩38,000

New 90-day low: ₩31,400

CEO

Tenure